Sonic Healthcare 1H21 Revenue $4.4bn, up 33% on the same time last year. EBITDA increased to $1.02bn and further growth of 5 – 10% into FY22 underpins our buy recommendation.
The balance sheet remains under-geared and we expect to see the company actively seeking M&A or JV opportunities.
You're not a member! Trial today
SHL trades on a forward yield of 3.8%
